Madrigal Pharmaceuticals, Inc.

CONSHOHOCKEN, Pa., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on September 1, 2026 and September 14, 2026 to a total of 27 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 1,800 shares of the biopharmaceutical company's stock, valued at approximately $967,000. A number of other large investors

Madrigal Pharmaceuticals, Inc. (MDGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Madrigal's only commercial drug, Rezdiffra, continues to grow sales. Institutional investors hold more than 95% of the stock's float.